Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China

Zheng, Xuehua; Xiao, Rong; Feng, Ying; Sun, Xikui; Li, Liang; Wang, Qian; Wang, Min; Liu, Wenkuan; Li, Chufang; Yang, Yiyu; Zhou, Rong; Lu, Jiahai; Feng, Liqiang; Chen, Ling

doi:10.1038/emi.2017.29

Cited by 23 publications

(38 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar distributions in seropositive rates and nAb titers of HAdV-4 or HAdV-5 between gender groups were observed (Fig. 3 ), in accordance with the results observed for other adenovirus types 4 , 29 . These results suggest that the sensitivity of men and women to infection by HAdV-4 or HAdV-5 was consistent and that the same level of nAbs could be generated by males and females after infection with HAdV-4 or HAdV-5.…”

Section: Discussionsupporting

confidence: 89%

“…To date, a total of 90 HAdV subtypes have been documented and classified into 7 species (A–G) according to their serological and molecular characteristics 1 – 3 . A variety of severe diseases with a broad range of symptoms, such as acute febrile respiratory disease, conjunctivitis, cystitis, gastroenteritis, myocarditis, and even life-threatening pneumonia are caused by HAdV infections in healthy adults and particularly in immunocompromised infants or young children 2 , 4 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

Wang¹,

Li²,

Wu³

et al. 2018

Emerging Microbes & Infections

101

View full text Add to dashboard Cite

An apparent increase in the frequency of human adenovirus type 4 (HAdV-4) infections among general populations has been observed over the past 10 years. However, available epidemiological data that may reflect previous viral circulation and assist in predicting potential outbreaks are sparse, particularly in mainland China and Africa. In this study, a convenient neutralization assay for use in the surveillance of historical HAdV-4 infections was established based on a recombinant luciferase-expressing virus. Subsequently, the neutralizing antibodies (nAbs) of 1013 healthy adult serum samples from China and Sierra Leone were evaluated. Our results showed that over 50% of the participants from China and nearly 70% of donors from Sierra Leone had detectable nAbs against HAdV-4 despite the few infection cases officially reported in these regions. Furthermore, the prevalence of nAbs to HAdV-4 is lower than that to HAdV-5, and both varied by geographic location. In addition, the seropositive rates of both HAdV-4 and HAdV-5 nAbs increased with age. However, the nAbs stimulated by HAdV-4 remained stable at low (≤200) levels among the different age groups, whereas moderate (201–1000) or high (>1000) nAb levels were produced by HAdV-5 and tended to decrease with age. These results elucidate the human humoral immune response against HAdV-4 and revealed that this virus may be an underestimated causative agent of respiratory disease among adults in China and West Africa, demonstrating the importance of HAdV-4 surveillance and providing useful insights for the future development of HAdV-4-based vaccines.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

Wang¹,

Li²,

Wu³

et al. 2018

Emerging Microbes & Infections

101

View full text Add to dashboard Cite

show abstract

“…The titers of neutralizing antibodies against Ad5 and Ad2 were detected with an MN assay as previously described 46 . Briefly, HEK293 cells were seeded into 96-well plates at 3 × 10 4 cells per well.…”

Section: Methodsmentioning

confidence: 99%

An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques

Feng

et al. 2018

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

Ebolavirus vaccines based on several adenoviral vectors have been investigated in preclinical studies and clinical trials. The use of adenovirus serotype 2 as a vector for ebolavirus vaccine has not been reported. Herein, we generated rAd2-ZGP, a recombinant replication-incompetent adenovirus serotype 2 expressing codon-optimized Zaire ebolavirus glycoprotein, and evaluated its immunogenicity in mice and rhesus macaques. rAd2-ZGP induced significant antibody and cell-mediated immune responses at 2 weeks after a single immunization. The glycoprotein (GP)-specific immune responses could be further enhanced with a booster immunization. Compared to protein antigens, Zaire ebolavirus GP and Zaire ebolavirus-like particles, rAd2-ZGP could induce stronger cross-reactive antibody and cell-mediated immune responses to heterologous Sudan ebolavirus in mice and rhesus macaques. In rAd2-ZGP-immunized macaques, GP-specific CD8+ T cells could secret IFN-γ and IL-2, indicating a Th1-biased response. In adenovirus serotype 5 seropositive macaques, rAd2-ZGP could induce robust antibody and cell-mediated immune responses, suggesting that the efficacy of rAd2-ZGP is not affected by pre-existing immunity to adenovirus serotype 5. These results demonstrated that rAd2-ZGP can be considered an alternative ebolavirus vaccine for use in adenovirus serotype 5 seropositive subjects or as a sequential booster vaccine after the subjects have been immunized with a recombinant adenovirus serotype 5-based vaccine.

show abstract

“…Outbreaks of HAdV-associated ARI (HAdV-ARI) in adults have been reported in communal living populations, including school, hospital, and military populations [3][4][5][6][7][8]. HAdV-55, a novel recombinant strain of HAdV-11 and HAdV-14 that causes ARI in adults [9], emerged as an epidemic strain in Asian and European countries from 2004 [6,8,[10][11][12][13][14][15][16][17][18]. In the Republic of Korea, fatal cases of HAdV-55 pneumonia among military personnel have been reported since 2012 [19], and a large military outbreak associated with HAdV-55 was observed in the winter of 2014 [20].…”

Section: Introductionmentioning

confidence: 99%

Ongoing outbreak of human adenovirus-associated acute respiratory illness in the Republic of Korea military, 2013 to 2018

Woo

et al. 2021

Korean J Intern Med

View full text Add to dashboard Cite

0000-0002-7464-9780 *These authors contributed equally to this work. Background/Aims: Human adenovirus type 55 (HAdV-55), an emerging epidemic strain, has caused several large outbreaks in the Korean military since 2014, and HAdV-associated acute respiratory illness (HAdV-ARI) has been continuously reported thereafter. Methods: To evaluate the epidemiologic characteristics of HAdV-ARI in the Korean military, we analyzed respiratory virus polymerase chain reaction (RV-PCR) results, pneumonia surveillance results, and severe HAdV cases from all 14 Korean military hospitals from January 2013 to May 2018 and compared these data with nationwide RV surveillance data for the civilian population. Results: A total of 14,630 RV-PCRs was performed at military hospitals. HAdV (45.4%) was the most frequently detected RV, followed by human rhinovirus (12.3%) and influenza virus (6.3%). The percentage of the military positive for HAdV was significantly greater than the percentage of civilians positive for HAdV throughout the study period, with a large outbreak occurring during the winter to spring of 2014 to 2015. The outbreak continued until the end of the study, and non-seasonal detections increased over time. The reported number of pneumonia patients also increased during the outbreak. Case fatality rate was 0.075% overall but 15.6% in patients with respiratory failure. The proportion of severe patients did not change significantly during the study period. Conclusions: A large HAdV outbreak is currently ongoing in the Korean military, with a trend away from seasonality, and HAdV-55 is likely the predominant strain. Persistent efforts to control the outbreak, HAdV type-specific surveillance, and vaccine development are required.

show abstract

Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China

Cited by 23 publications

References 46 publications

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques

Ongoing outbreak of human adenovirus-associated acute respiratory illness in the Republic of Korea military, 2013 to 2018

Contact Info

Product

Resources

About